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The central nervous system (CNS) is now known to actively communicate with the immune system to control
immune responses both centrally and peripherally. Within the CNS, while studies on glial cells, especially microglia,
have highlighted the importance of this cell type in innate immune responses of the CNS, the immune regulatory
functions of other cell types, especially neurons, are largely unknown. How neuroimmune cross-talk is
homeostatically maintained in neurodevelopment and adult plasticity is even more elusive. Inspiringly,
accumulating evidence suggests that neurons may also actively participate in immune responses by controlling
glial cells and infiltrated T cells. The potential clinical application of this knowledge warrants a deeper
understanding of the mutual interactions between neurons and other types of cells during neurological and
immunological processes within the CNS, which will help advance diagnosis, prevention, and intervention of
various neurological diseases. The aim of this review is to address the immune function of both glial cells and
neurons, and the roles they play in regulating inflammatory processes and maintaining homeostasis of the CNS.
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Our understanding on the reciprocal relationship between
the nervous and immune systems has developed rapidly
within the past decade. Inflammatory response has been
associated with pathological processes in a wide range of
brain disorders, including not only the conventional in-
flammatory conditions in autoimmune diseases, traumatic
brain injuries, stroke, and neurodegenerative diseases
[1,2], but more importantly also neurodevelopmental
defects in schizophrenia, epilepsy, and autism [3-5]. How-
ever, immune responses are specialized within the brain
and differ considerably from those in the periphery. Such
differences endow the central nervous system (CNS) with
an immune-privilege status, and provide challenges for
therapeutic interventions to various CNS diseases [6-8].
Hence, a thorough insight into the immunological pro-
cesses within the CNS and their involvement in neurode-
velopment and neuropathology is pivotal for current
researchers. This article aims at providing readers the* Correspondence: li.tian@helsinki.fi
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reproduction in any medium, provided the orupdated knowledge of the immune regulatory functions of
the CNS residential cells: glia and neurons. Since immune
functions of glia are much better known than those of
neurons [4,5,9], we will emphasize more on the latter ones
in this review. We posit that neurons, glia, and peripheral
immune cells form an integrative network to actively regu-
late immunological processes that affect brain functions,
which will be dissected in detail here.Glia as innate immune cells in the CNS
Although the CNS is relatively secluded from the periph-
eral immune system, it has its own residential immune
network, in which glial cells (mainly microglia and astro-
cytes) not only serve supportive and nutritive roles for
neurons, but also defend the CNS from stress and patho-
genic insults by transiently up-regulating inflammatory
processes [9]. These processes are usually kept in check by
other endogenous anti-inflammatory and neuroprotective
responses that return the CNS back into homeostasis.
However, excessive or prolonged glial activation results in
a more severe and chronic neuronal damage that eventually
propagates neuroinflammation and neurodegeneration,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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roprotection and neurotoxicity [10]. This is substantiated
by studies showing that similar to chronic neurodegenera-
tive diseases, microglia in the aged, but otherwise healthy
brain are in a more reactive state compared with the
younger cohorts. These already ‘primed’ microglia release
excessive amounts of pro-inflammatory cytokines upon
stimulation, which subsequently exaggerates degenerative
changes [11,12].
It is interesting to note that glial cells are not only able
to directly detect invaded pathogens in the CNS, but can
also sense the immune responses occurred in the periph-
ery through cytokines and chemokines, which alert the
CNS through humoral and/or neurochemical pathways.
Glia in turn elicit a broad spectrum of chemokines and
cytokines themselves, which cause or exaggerate the so-
called sickness behaviors or the analogous depressive
symptoms [13,14], indicating an active communication of
the central glial cells with the peripheral immune system.
Under homeostatic conditions, the peripherally and cen-
trally synthesized inflammatory proteins play key roles in
orchestrating the adaptive reactions of the CNS towards
physical or emotional stresses [13,14]. Yet again, they can
be harmful for neuronal development and plasticity when
the immunological process turns more chronic or in those
individuals who are predisposed to certain neurological
diseases, such as schizophrenia, epilepsy, and autism, and
therefore do not tolerate the immune stimulations as well
as the healthy people (Figure 1) [5,11,13,15].
Microglia
Microglia comprises 5% to 20% of all glial cells in vari-
ous brain regions. As commonly known, they are theFigure 1 A simplified schematic illustration of the interaction betwee
the normal (a) and pathological conditions (b). Healthy neurons are ab
Meanwhile both astrocytes and microglia help maintain the neuronal activ
that neurons lose their controlling ability but instead deliver damage signa
through inflammation. The cross-talk among astrocytes and microglia themmajor phagocytic cells that provide the first line of de-
fence for the CNS [16]. In respect to neuroimmune
cross-talk, microglia play the most direct and perhaps
also the most important role in sensing and modulating
neuronal activities. Resting microglia acquire a ramified
but nevertheless active morphology normally, with min-
imal expression of myeloid-monocytic markers such as
Fc receptors-cluster of differentiation (CD) 32 and
CD64, complement receptors (CR)-3 and −4, (also
named as CD11b and CD11c integrins, respectively),
major histocompatibility complex (MHC) class I and II,
and CD45 [17] (Table 1). Once challenged by inflamma-
tion, microglia become rapidly ameboid and up-regulate
a variety of cell surface receptors involved in innate im-
mune responses. These receptors include pattern recog-
nition receptors (PRR), such as toll-like receptors (TLR)
and receptors for advanced glycation end products
(RAGE) and scavenger receptors (CD36, CD91), as well
as phagocytic receptors, such as CR-3, -4, and triggering
receptor expressed on myeloid cells (TREM) (Tables 1
and 2) [17,18].
Phagocytosis is an important mechanism for microglia
to control neuronal apoptosis. When apoptosis of neurons
occurs, for example, at the early developmental stage, or
due to neurodegeneration, clearance of apoptotic cell deb-
ris in time through phagocytosis is vital for the reminis-
cent neurons to avoid collateral inflammation-induced
damage [19,67]. Apoptotic cells express cell surface mo-
lecular patterns that act as ‘eat me’ signals. These signals
are recognized by microglial PRRs, which rapidly initiate
clearing processes [18]. On the other hand, insufficient
phagocytic clearance of cell debris following neuronal in-
jury is an important pathogenetic factor in propagation ofn the trios of neurons, astrocytes, and microglia in the CNS under
le to tightly regulate the activation of their neighboring glial cells.
ity. Under various diseased conditions, this homeostasis is broken so
ls to glial cells, which in turn may exacerbate neuronal damage
selves and its aftermath on neurons is currently not very clear.
Table 1 Immune properties of glia and neurons in the CNS
Properties Microglia Astrocyte Neuron
Innate immunity
PRRs High [16-19] High [20] Low [21]
Phagocytic receptors High [16-19] Low [20] Unknown
Cytokine production
Pro-inflammatory Yes [16-19] Yes [10,20,22] Yes [8,23]
Anti-inflammatory Yes [16-19] Yes [10,20,22] Yes [23-28]
Adaptive immunity
MHC classes I & II [17,29] Inducible I & II [22,29-31]
Low/inducible
I [32]
Inducible
Co-stimulatory molecules Inducible [17,29] Low/inducible Unknown
Antigen presentation Yes [17,29] Controversial [29] Unknown
T-cell differentiation Th1, Th2 [17,29,33] Th2 [33,34], Largely
unknown
Th1 [33,34],
Treg [35,36]
Induction of apoptosis
T cells Yes [18,29,37-41] Yes [18,29,37-41] Yes [18,29,37-41]
Microglia Yes [18,29,37-41] (self-limiting) Yes [18,29,37-41] Yes [18,29,37-41]
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Alzheimer’s disease (AD) [16,19].
Besides controlling neuronal apoptosis, microglia se-
crete a wide variety of cytokines, complements, and
growth factors that have been implicated in regulating
synaptic formation and plasticity [67]. With the help of
the complement system, unwanted synapses are effi-
ciently removed by phagocytosis under both develop-
mental and pathological conditions [68]. Mice deficient
in complement C1q or C3 exhibited sustained defects in
elimination of the CNS synapses [44]. More importantly,
the orthodox view that microglial activity is only relevant
for the pathological processes of neuronal pruning has
been overturned by the recent evidences showing that
they are highly sensitive for the neighboring neuronal
activities and control dendritic spine density under
physiological conditions [69,70]. Furthermore, a recent
elegant work by Derecki et al. demonstrated that micro-
glia from bone marrow of wild-type mice attenuated
Rett syndrome, an X-linked autism spectrum disorder
[71]. Undoubtedly, emerging evidences with the help of
modern imaging and analytical technologies will shed
light into the physiological functions of microglia in the
coming years.
Another important function of microglia is the presen-
tation of foreign antigens to T lymphocytes. In the nor-
mal CNS, antigen presenting cells (APC) are mainly
confined to dendritic cells and macrophages located in
the meninges, choroid plexuses, and perivascular spaces
[29]. MHC class I and II molecules are expressed at lowlevels by microglia, as they are actively down-regulated
by the immune-quiescent microenvironment of the
CNS. However, upon activation, these molecules are up-
regulated together with the co-stimulatory receptors
CD40, CD80 (B7-1), CD86 (B7-2), and leukocyte
function-associated antigen-1 (LFA-1, CD11a/CD18 in-
tegrin), which subsequently induces optimal APC func-
tions and T-cell activation (Tables 1 and 2) [17,29].
Unarguably, microglial cells have to be kept in check
under normal conditions. Furthermore, as an excessive
inflammation causes disastrous bystander damage to the
CNS, activation of microglia under pathophysiological
conditions of stress or mild malaise has to be restricted
by counter-regulatory mechanisms to resurrect the CNS
homeostasis (Figure 1) [16]. Unfortunately, how the bal-
ance is achieved and how to beneficially modulate it in
psychological and neurological diseases are still unclear
so far.
Astrocyte
Astrocytes have been traditionally viewed as supportive
cells for neurons, which are responsible for the CNS
homeostasis and neuronal functions [72] (Figure 1a).
Their functions as innate immune cells are somehow
less appreciated as compared to microglia. Nevertheless,
astrocytes have been known to form the glia limitans
around blood vessels, thereby restricting the entry of
immune cells through the blood-brain barrier (BBB)
into the CNS parenchyma [73]. Emerging evidences
have highlighted the importance of this cell population
Table 2 Pro- and anti-inflammatory molecules expressed by glia and neurons
Properties Promotion of inflammation Inhibition of inflammation
Microglia
Soluble factors TNF, IFN-γ, IL-1β [16-19]; IL-4, IL-10, IFN-β, TGF-β [16-19];
CXCL1,2,12, CCL2,5,10,19 [42]; BDNF, GDNF [42];
Glutamate; NO, ATP [16-19] TIMPs [43]
MMPs [43]; Complements [18,44];
HMGB1, heat-shock proteins [25,45-47]
Membrane proteins TLRs, RAGE, LFA-1, MAC-1, CRs,
FcRβ [16-19,21,25,45-47]
CD45, CD91, CD200R, CD172a [18,48];
CX3CR1 [49]; TREM-2 [50]; FasL, Fas [38,39]
Astrocytes
Soluble factors TNF, IFN-γ, IL-1β [10,20,22]
CXCL1,2,12, CCL2,5,10,19 [20,42];
IL-4, IL-10, IFN-β, TGF-β [10,20,22]
Proteoglycans [51,52];
Glutamate; NO, ATP; MMPs [10,20,22];
Complements [18,20,44] HMGB1,
heat-shock proteins [25,45-47]
BDNF, GDNF [42,53,54]; TIMPs [43]
Membrane proteins TLRs, RAGE, ICAM-1, CRs [21,25,46] FasL [37,38], Complement
inhibitors [20]
Neurons
Soluble factors CXCL10, CCL21 [8,23,42]; TGF-β [27,28]; CX3CL1 [49,55];
Glutamate, dopamine [23]; GABA [56,57]; VIP [58,59]; NE
NO, ATP; Substance P [23]; MMPs [43];
HMGB1, heat-shock proteins [25,45-47]
[60,61];
Proteoglycans [51,52];
NGF, BDNF, NT3, GDNF, CNTF [42,53,54]
Membrane proteins TLRs [21] CD22 [62], CD47 [63,64], CD200 [48],
ICAM-5 [65,66], FasL [37,38]
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responses [20].
Astrocytes express a variety of PRRs involved in innate
immunity, including TLRs, scavenger receptors, man-
nose receptors, and CRs (Tables 1 and 2) [20]. Following
PRR engagement, astrocytes secrete cytokines, chemo-
kines, and neurotrophins that target neighboring glial
cells and neurons [10,20]. Released cytokines also pro-
mote the leakage of BBB, resulting in the recruitment of
immune cells from the blood circulation into the CNS
parenchyma. These altogether amplify both the initial in-
nate immune responses and the upcoming adaptive im-
mune responses, which can result in the elimination of
infectious or injurious insults and restoration of tissue
integrity or scar formation [74].
Astrocytes are active players in the AD and multiple
sclerosis (MS) [22,75]. Under pathological conditions,
astrocytes undergo a series of structural and functional
changes collectively referred to as astrogliosis. Amyloid
β-peptide (A-β) plays an important role in astrocyte
stimulation [76]. Accumulation of astrocytes around the
senile plaques and neurofibrillary tangles is one of the
hallmarks of the AD [75]. Upon A-β stimulation, astro-
cytes secrete various chemokines that recruit microglia
and monocyte/macrophages to the plaques with theconcomitant release of neurotoxins and pro-inflammatory
cytokines that contribute in concert to neurodegeneration
[75]. Astroctyes are also involved in the MS disease
through release of pro-inflammatory cytokines, matrix
metalloproteinases (MMP), and free radicals that result in
recruitment of autoimmune cells, oligodendrocyte de-
struction, and demyelination (Table 2) [22].
Another interesting, yet controversial, property of
astrocytes is their antigen-presenting ability. In vitro
studies have shown that astrocytes express low levels of
MHC and co-stimulatory molecules upon stimulation by
cytokines, and are capable of processing and presenting
myelin protein epitopes to T cells, inferring that they
can also be APCs [30,31]. However, given the more effi-
cient antigen presentation capabilities of microglia and
other infiltrating APCs in the CNS, the in vivo signifi-
cance of this function of astrocytes is unclear (Table 1)
[9,22,29].
Despite of these controversies, the ability of astrocytes
to regulate the antigen-presenting activities of other APCs
and T-cell activation has been clearly established. The fact
that the expression levels of MHC and co-stimulatory
molecules are low even after stimulation in vitro suggests
that astrocytes may be prone to induce T helper (Th) 2 ra-
ther than Th1 responses. Indeed, earlier studies showed
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both Th1 and Th2 cells, astrocytes stimulate only Th2
cells [33]. Microglia and astrocytes also produce chemo-
kines that differentially affect the recruitment of Th1 and
Th2 cells (Tables 1 and 2) [34].
Additionally, astrocytes have been shown to induce an-
ergy of Th cells via cytotoxic T-lymphocyte antigen 4
(CTLA-4, CD152) [77] or promote recruitment and pro-
liferation of regulatory T cells (Treg) via the anti-
inflammatory cytokine transforming growth factor β
(TGF-β) [35] and chemokine CXCL12 (stromal cell-
derived factor-1, SDF-1) [36]. Astrocytes can also secrete
other anti-inflammatory cytokines or soluble factors, in-
cluding interleukin (IL)-10, interferon (IFN)-β, and neu-
rotrophins, which are able to suppress T cell and
microglial activation (Table 2) [10,20,22]. So it seems
that a complex network of interactions between neurons,
astrocytes, microglia, and T cells is involved in determin-
ing the balance of pro- vs. anti-inflammatory signals,
which in turn affect the outcome of immune responses
within the CNS.
Collectively, the above information indicates that both
microglia and astrocytes play an active and dual role in
the CNS inflammatory diseases. They not only have the
ability to enhance immune responses and promote neu-
rodegeneration, but can also be protective and limit the
CNS inflammation.
Neurons actively regulate innate and adaptive immune
responses in the CNS
While a plethora of data has highlighted the immune-
regulatory functions of microglia and astrocytes, the
roles that neurons play in this arena are under-toned
[8,23]. Neurons have primarily been regarded as victims
of immune attack, and their participation in the CNS
immune responses as passive.
Nevertheless, the CNS has been known to regulate
peripheral innate immune responses through hormonal
and neuronal circuits [24,25]. The neuroendocrine-
mediated stress responses induced by infection or trau-
matic injuries generally inhibit innate immune responses
at the systemic level [24]. The sympathetic and parasym-
pathetic nervous systems also sense injury and infection
at the regional level, and reflectively modulate immune
responses through the adrenergic and cholinergic anti-
inflammatory pathways [24,25]. It is noteworthy that the
major neuroendocrine hormones and neurotransmitters
that control the peripheral immunity also play important
roles in controlling the functions of various CNS cells,
not only in response to immune stimuli, but also to
stress and emotional arousal, in order for an organism
to adapt to its environment. Therefore the central roles
they play in regulating immune responses of the CNS
should not be overlooked [26].Reciprocally, besides behaving as sentinels to fend off
pathogens, both central and peripheral immune cells
participate in neurodevelopment and cognitive functions
of the brain as well. This is substantiated by the recent
evidences that microglia intimately interact with neurons
to monitor their activities, as previously discussed. Add-
itionally, peripheral adaptive immune cells may also
regulate neurogenesis, learning, and emotional behaviors
of animals [78]. Deficiency in the adaptive immunity of
severe combined immunodeficiency (SCID) or recom-
bination activating gene (RAG)-1(−/−) mice is associated
with reduced neurogenesis and impaired learning and
memory [79,80]. Systemic depletion of CD4+ T cells led
to significantly reduced hippocampal neurogenesis and
impaired reversal learning in the Morris water maze,
and repopulation of RAG-2(−/−) mice with CD4+ T cells
increased neural precursor cell proliferation [81]. Re-
cently, immune activity has also been found associated
with programming of the hypothalamus-dependent
stress axis. Germ-free mice, which have the ill-balanced
immune system, were shown to display increased motor
activity and reduced anxiety as compared to mice with a
normal gut microbiota [82]. Furthermore, repeated stress
increased blood pressure in wild type but not RAG-1
(−/−) mice, and adoptive transfer of T cells to RAG-1
(−/−) mice restored blood pressure elevation in response
to stress [83].
Bearing in mind that the CNS contains BBB that nor-
mally prevents immune cells from penetration [6,7], as
often quoted by some hard-cored neuroscientists, it
remains as a question as how the peripheral immune
cells keep the communication with the CNS cells. One
possibility is a direct humoral route mediated by circu-
lating cytokines and/or chemokines since cytokines and
their receptors are expressed by glial and neuronal cells
in the adult CNS and are important mediators of various
brain and behavioral functions [84]. Alternatively, in-
nervation by the autonomic nerve fibers provides a re-
flective loop between the brain and the peripheral blood
vessels and gut epithelia [85]. Although mechanisms for
many of the above-described phenomena have not been
well-characterized from a holistic level so far, it should
not be ignored that accumulating clinical evidences have
strongly suggested the correlation of narcolepsy, depres-
sion, irritable bowel syndrome, autism, and schizophre-
nia with immune activation [4,5,14].
One can envisage that the regulation of such immune
activity is crucial as too little or too much can both lead
to impaired neurogenesis and cognitive functions. Since
neurons in the brain are very sensitive to changes in
their surrounding milieu, and are poor to regenerate
once damaged, a number of mechanisms exit to limit
the immune-mediated neurotoxicity and the collateral
tissue damage, which were collectively denoted as
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advances in this research field and summarize the
mechanisms on neuronal regulation of innate and adap-
tive immunities. We believe that the CNS actively inter-
acts with the immune system and provides several
specific mechanisms to regulate the central immune
responses, which involves not only microglia and astro-
cytes, but also neurons themselves (Tables 1 and 2;
Figure 1a) [8,23].
Soluble factors and their receptors
Neurons may inactivate T cells and microglia by both
contact-dependent and -independent mechanisms [8].
Given that peripheral immune cells do not normally
penetrate into the brain parenchyma, soluble factors
provide an important means for the neuroimmune
cross-talk. There are a number of neuronal soluble fac-
tors that potentially attenuate T- and microglial cell acti-
vation. These include anti-inflammatory cytokines [86],
chemokines [42], neuropeptides [58], neurotrophins
[42], and neurotransmitters [23] (Table 2).
TGF-β is the major anti-inflammatory cytokine needed
for an organism to nurture Treg cells and keep auto-
immune T cells at bay under the steady state. In the
CNS, it is constitutively expressed in neurons [27,86]. Its
importance in down-regulating microglial and auto-
immune T-cell responses is substantiated by increased
microglial activity and neuronal loss in the brains of
TGF-β-deficient mice [28]. Additionally, fractalkine
(CX3CL1, neurotactin) is the predominant chemokine
expressed and released by neurons in the CNS, whereas
its receptor CX3CR1 is primarily expressed in microglia.
Fractalkine and its receptor play an important role in
mediating interaction between neurons and microglia
[55], which, on the one hand, controls inflammatory
neurotoxicity in the brain as CX3CR1-deficient mice
showed a massive activation of microglial cells upon
repeated lipopolysaccharide (LPS) injection [49], and on
the other hand, regulates the neuronal plasticity as the
dendritic spines were increased in CX3CR1-deficient
mice due to the inefficient synaptic pruning [70]. Fur-
thermore, stressed neurons also secret semaphorin-3A
and other substances to induce the apoptosis of acti-
vated microglia [87-89].
Neurotrophins are another group of soluble factors
used by neurons to control immune cell functions. They
play critical roles in neuronal survival, migration, and
differentiation, and are potential drugs for the treatment
of neurodegenerative diseases [90]. One aspect of their
multiple effects on neurons is dampening inflammation-
induced damage in the CNS. Among them, nerve
growth factor (NGF) and brain-derived neurotrophic
factor (BDNF) were investigated. NGF influences B-cell
and T-cell functions and regulates macrophagemigration into inflamed lesions outside of the nervous
system [91]. Within the CNS, NGF was previously
shown to inhibit MHC class II expression in microglia
[53]. And BDNF was demonstrated to down-regulate the
co-stimulatory molecules B7 and CD40 expression in
microglia [54].
Additionally, neurons are equipped with various im-
munosuppressive neuropeptides and neurotransmitters,
including vasoactive intestinal peptide (VIP), norepin-
ephrine (NE), and γ-aminobutyric acid (GABA). VIP is a
widely distributed neuropeptide with neuroprotective
properties by inhibition of proinflammatory mediators,
such as IL-6, tumor necrosis factor (TNFα), IL-12, and
nitric oxide (NO), in vivo in various murine models of
Parkinson’s disease, acute brain trauma, neuroinflamma-
tion, and cerebral ischemia [59]. NE is a catecholamine
with roles both as a hormone and as a neurotransmitter
that dampens cellular immunity systemically and sup-
presses neuroinflammation in the brain [60]. LPS-
induced TNFα production in hippocampus is inversely
correlated with the release of NE in an animal model of
depression [61]. Furthermore, GABA, a main inhibitory
neurotransmitter in the brain, has been shown to attenu-
ate LPS-induced IL-6 and IL-10 production in microglia
[57], and affect the entry of pathogenic T lymphocytes
into the brain and T-cell proliferation [56].
Cellular interactions
Neuronal membrane glycoproteins, such as CD22
[62,92], CD47 [63,64], CD200 [48,93], and neural cell ad-
hesion molecule (NCAM) [94,95] have been shown to
prevent microglial activation through interaction with
their respective counter-receptors (Table 2).
The immunoglobulin superfamily (IgSF) member
CD200 (OX2) is broadly expressed in neurons, endothe-
lial, and immune cells, while its receptor, CD200R,
which is also an IgSF molecule, is expressed predomin-
antly by cells of the myeloid lineage, including microglia
[48] and T cells [96]. Knocking out CD200 in mice
results in a spontaneous microglial activation [48]. Simi-
larly, antibody-mediated blocking of CD200R also leads
to an aggravated clinical course of experimental auto-
immune encephalomyelitis (EAE), accompanied by
increased infiltration of T cells and macrophages [48].
Blocking CD200R on macrophages in vitro leads to
enhanced IFN-γ-induced release of IL-6 and neuronal
cell death in co-cultures with hippocampal neurons
expressing CD200 [93].
Another IgSF and sialic acid-binding molecule, CD22,
has been implicated in attenuation of the CNS immune
responses as well. CD22 is expressed in cultured cortical
neurons, and might mediate the binding of neurons to
microglia through CD45 [62]. Ligation of microglial
CD45 by CD22 has been shown to prevent the LPS-
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cytokine TNF [62,92].
Furthermore, the integrin-associated protein CD47
may also be important in down-regulating immune
responses in the CNS. CD47 has been identified as a cel-
lular ligand for the signal regulatory protein-α (SIRPα
CD172a, which is also an IgSF member. Studies on
SIRPα-deficient mice reveal that SIRPα is a negative
regulator of macrophage phagocytosis [63], and ligation
of monocyte SIRPα by CD47 down-regulates their TNF
production [64].
Additionally, when mixed with glial cells in vitro, neu-
rons inhibit the LPS-stimulated production of NO and
TNF by glial cells. This effect is partially mediated
through the IgSF adhesion molecule NCAM [94,95].
Chronic stimulation and interaction with apoptotic neu-
rons induce microglial cells to release neuroprotective
agents while inhibiting the production of NO and pro-
inflammatory cytokines [1]. Furthermore, the receptor
TREM-2 on microglia was shown to mediate the phago-
cytosis of apoptotic neurons while decreasing microglial
pro-inflammatory responses, although its neuronal lig-
and has not been identified yet [50,97].
Other mechanisms
Although experimental evidences supporting a direct
interaction of neurons with T cells to prevent their
antigen-dependent and -independent activation are cur-
rently still scant, this does not exclude the possibility that
the T-cell-bearing counter-receptors for the above-
mentioned neuronal molecules may regulate the ampli-
tude of T cell receptor (TCR)-mediated activation of T
cells [8]. We have previously shown that the neuronal
intercellular adhesion molecule-5 (ICAM-5), an integrin
ligand that regulates dendritic filopodia elongation and
spine plasticity [65,98], down-regulates T-cell activation
through interfering with the co-stimulatory function of in-
tegrin LFA-1 [66] (Table 2). In addition, semaphorins and
their receptors plexins, in concert with neuropilin, have
also been shown to attenuate T-cell activation and miti-
gate EAE [89,99-102]. Alternatively, neurons have been
shown to convert T cells into Treg cells irrespective of
their antigen specificity, which in turn suppresses EAE
(Tables 1 and 2) [103,104]. And as suggested in the previ-
ous section, T-cell derived CD200R may also be important
in dampening autoimmune responses in EAE [48].
Furthermore, neurons, microglia, and astrocytes have
been shown to up-regulate Fas ligand (FasL, CD95L)
under inflammatory conditions, which can induce apop-
tosis of activated T or microglial cells through the FasL-
Fas pathway [37,38]. Administration of anti-FasL anti-
body to Lewis rat with EAE in the clinically recovery
phase has been shown to reduce T-cell apoptosis, in-
crease accumulation of T cells and macrophages at thesite of inflammation, and delay spontaneous recovery of
the animals [39]. Both T and microglial cells are more
sensitive to Fas-dependent cell apoptosis than neurons
and astrocytes [40,41], indicating the robustness of the
later two cell types in limiting inflammatory insults
through this pathway (Table 2).
It should be noted that the ability of neurons to limit
immune responses in the CNS is largely dependent on
their own integrity. At the early stage of pathological con-
ditions, self-limiting machineries, such as apoptotic de-
struction of activated T cells, microglial cells, and injured
neurons, may initially be able to keep the balance of pro-
tection vs. damage [18]. Once this is compromised, the in-
flammatory processes will be accelerated by neurons
which turn on the expression of multiple pro-inflammatory
cytokines and neurotoxic proteins such as A-β peptide,
heat-shock proteins, and high mobility group box 1
(HMGB1, amphoterin) (Table 2; Figure 1b) [25,45]. These
endogenous ‘dangerous signals’, also termed as damage-
associated molecular pattern (DAMP) molecules, then agi-
tate the already activated glial cells, and hence probably lead
to their over-activation, which eventually exacerbates neur-
onal damages (Table 2) [46,47].
Conclusions
Neurons, glial and immune cells form a coordinated
network to maintain the homeostasis and restrict neu-
roinflammation in the CNS. This integrative network is
not only involved in the pathogenesis of neuroinflamma-
tion, but more importantly, may also play a major role
in the normal brain functions. The particular impact of
glial and immune cells on the physiological vs. patho-
logical process in the CNS is dependent on a number of
factors that influence their state of activation. Here, we
have summarized that neurons, the major effector cells
for cognitive and motor function of an organism, provide
environmental milieu that regulate glial and immune cell
activation. Since inflammation is a double-edged sword
for the CNS, improved knowledge on both beneficial and
detrimental factors provided by neurons for the progress
of inflammation should help develop better ways to treat
various neurological diseases.
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